Trial Profile
PROSPER: Prospective Real World Outcomes Study of Hepatic Encephalopathy Patients' Experience on Rifaximin-α (TARGAXAN/XIFAXAN) 550 mg
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Oct 2020
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Hepatic encephalopathy
- Focus Therapeutic Use
- Acronyms PROSPER
- Sponsors Norgine
- 29 Aug 2020 Results presented at The International Liver Congress 2020
- 12 Dec 2018 Status changed from recruiting to completed.
- 29 Jan 2018 According to a Norgine media release, study design is publised in the Hepatology Medicine and Policy Journal. Results from the study is anticipated in 2018.